Giliad Sciences Articles
Setback for Merck & Co as vicriviroc disappoints in Ph III
22 January 2010
FDA advisory committee backs safety and efficacy of Gilead’s aztreonam for cystic fibrosis
11 December 2009
Gilead and GlaxoSmithKline to commercialize Viread for chronic hepatitis B in key Asian countries; update on Avodart
26 November 2009
US mid-caps Biogen, Forest and Gilead post in-line or better-than-expected three-month results
21 October 2009
Conditional EU Marketing Authorization for Gilead’s Cayston
24 September 2009
Mylan's Matrix gets tentative FDA approval under PEPFAR for generic Atripla HIV Treatment
19 August 2009
Gilead files 2nd patent suit against Teva
15 May 2009
Gilead set to benefit from Tamiflu orders
1 May 2009
Profit up 22% at Gilead on pipeline strength
27 April 2009
Gilead completes CV Thera acquisition
21 April 2009
Achillion granted US patent for NS4A antagonist in hep C
17 April 2009
Gilead completes CV Thera tender offer
15 April 2009
Teva files ANDA on Gilead
7 April 2009
Gilead progresses on CV Thera buy
2 April 2009
Gilead begins enrolling into Ph II trial of cicletanine
30 March 2009
Gilead falls 2.4% as CHMP rejects CF drug
30 March 2009
Japan stock market week to March 16, 2009
23 March 2009
US DoJ declines to intervene in Gilead law suits
23 March 2009
Gilead to acquire CV Thera for $1.4B
16 March 2009
FDA reiterates position on Gilead response
23 February 2009
Gilead presents HIV drug-booster at CROI
16 February 2009
China imports two branded ARVs
26 January 2009
Gilead files patent suit against Teva
22 December 2008
Teva challenges two of Gilead's Truvada patents
24 November 2008
Viread suppresses HBV through 96 weeks
10 November 2008
Stock Commentary - New York week to Oct 20, 2008
27 October 2008
Gilead up almost 30% on HIV franchise
27 October 2008
Gilead names Seigo Izumo as SVP, CV unit
22 September 2008
FDA asks Gilead for another clinical study of aztreonam
22 September 2008
Stock Commentary - New York week to Sept 8, 2008
15 September 2008
US FDA approves Gilead's Viread chronic HBV infection
18 August 2008
Gilead leads in selling Atripla in new countries
11 August 2008
Gilead recruits for Ph III elvitegravir HIV trial
4 August 2008
Gilead profits up 9% on HIV franchise sales
28 July 2008
HIV/AIDS drug prices frozen for US agencies
9 June 2008
Gilead acquires Navitas' cicletanine assets
9 June 2008
Strong Ph III data for Gilead's Viread
5 May 2008
Robin Washington joins Gilead Sciences
28 April 2008
Brazil to bypass patent for ARV drug Viread
28 April 2008
Gilead record sales push revenue up 22%
28 April 2008
Gilead recruits regional general managers
7 April 2008
India NGOs at war with cancer drug patents
7 April 2008
Gilead files MAA for aztreonam nebulizer
17 March 2008
Gilead plans $500M share repurchase
10 March 2008
Gilead's sales up 40%; Viread patent challenge
4 February 2008
EC approves B-MS/Gilead's Atripla
24 December 2007
HIV/AIDS drug Atripla debuts in UK
24 December 2007
First generic Viread cleared by FDA
24 December 2007
Cipla ARV price cut does not appease campaigners
24 December 2007
Gilead submits inhalable aztreonam NDA
26 November 2007
Better 48-week efficacy with Viread vs Hepsera
21 November 2007
Stock Commentary - New York week to Nov 12, 2007
19 November 2007
Stock Commentary - New York week to Oct 29, 2007
5 November 2007
Less side effects with switch from Combivir to Truvada
5 November 2007
Gilead announces $3 billion share buyback
29 October 2007
Gilead's 3rd-qtr 2007 revenue jumps 41%
29 October 2007
Atripla approved in Canada for HIV-1
22 October 2007
Merck & Co's Cancidas comparable to AmBisome in IFI
1 October 2007
AHF blames drug firms for slow ARV uptake
24 September 2007
Small number of combination drugs reaching the Japanese market
24 September 2007
India's Cipla pricing claims disputed
3 September 2007
India's regulators investigate Cipla pricing claims
3 September 2007
Parion licenses its ENaC inhibitor to Gilead in deal worth up to $164M, gets $5M up front
3 September 2007
Truvada/Sustiva cuts viral load vs Combivir/Sustiva
6 August 2007
William Freytag joins Aspreva as chairman and CEO
16 July 2007
Gilead completes $1 billion stock repurchase
25 June 2007
Gilead's Viread shows promise in HBV trial
18 June 2007
Gilead's Viread "non-inferior" to Hepsera
11 June 2007
Gilead's CF drug positive in Ph III trial
4 June 2007
Gilead reports full data from CF drug trial
30 April 2007
Gilead's 1st-qtr 2007 net income sky-rockets 55%
30 April 2007
Gilead Sci to open new $80.6M plant in Dublin, Ireland
16 April 2007
Genelabs narrows net loss in 2006 to $8.7M
9 April 2007
GSK submits Gilead's ambrisentan to CHMP
2 April 2007
Gilead's GS 92 to enter Ph I clinical testing
26 March 2007
Gilead Sciences makes executive appointments
19 March 2007
Gilead's GS 9137 lowers HIV viral load
12 March 2007
Gilead's ambrisentan NDA accepted by FDA
26 February 2007
Gilead/Achillion stop GS 9132 despite trial meeting endpoint
19 February 2007
Gilead's share price up on strong 4th-qtr sales
12 February 2007
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
